ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1366	National Cancer Institute	Html	en	Pruritus (PDQ®)–Health Professional Version	Expert-reviewed information summary about pruritus (itching of the skin) as a complication of cancer or its treatment. Approaches to the management and treatment of pruritus are discussed.	pruritus 0.960641 second-generation antihistamines 0.585479 skin type 0.575303 atopic dermatitis 0.673145 skin surface 0.599366 worst pruritus 0.717892 atopic dermatitis population 0.574946 severe non-dermatological pruritus 0.718081 skin lipids 0.573883 Acad Dermatol Venereol 0.589376 primary dermatitis 0.600506 significant skin breakdown 0.59383 blood flow 0.584198 allergic skin reactions 0.594569 patients 0.575543 Dermatol Venereol Leprol 0.585578 placebo-controlled study 0.5912 radiation therapy 0.686843 Int J Dermatol 0.586614 Pain Symptom Manage 0.63754 healthy skin 0.593613 dry skin 0.639653 neuropathic pruritus 0.745005 et al. 0.592668	skin cleansing 0.573636 treatment 0.596222 skin reactions 0.599238 Oncol Nurs Forum 0.699339 skin dermatitis 0.603221 Opioid-induced Pruritus 0.704011 skin 0.704869 uraemic pruritus 0.705232 PUBMED Abstract 0.858232 Altered skin integrity 0.588103 Skin care 0.624412 Acta Derm Venereol 0.596823 pruritus relief 0.700635 itch 0.57584 allergic contact dermatitis 0.578553 skin hydration 0.574125 Clin Exp Dermatol 0.593566 skin change 0.583853 aggravates dry skin 0.598514 chronic idiopathic urticaria 0.638535 cholestatic pruritus 0.69774 Dermatol Ther 0.606265 intractable pruritus 0.703673 chronic pruritus 0.736276	CLICK HERE
1446	National Cancer Institute	Html	en	Oral Complications of Chemotherapy and Head/Neck Radiation (PDQ®)–Patient Version	Expert-reviewed information summary about oral complications, such as mucositis and salivary gland dysfunction, that occur in cancer patients treated with chemotherapy or radiation therapy to the head and neck.	cancer treatment 0.700679 oral mucositis pain 0.483396 tissue 0.465551 chemotherapy 0.631313 blood cell count 0.467595 mouth problems 0.466009 PDQ Oral Complications 0.468892 oral health exam 0.469677 mouth sores 0.537291 infections 0.470414 teeth 0.49264 neck radiation therapy 0.476468 high-dose chemotherapy 0.598756 cancer information summary 0.466904 oral mucositis 0.510415 stem cell transplant 0.72121 oral complications 0.763758 patients 0.61166 cancer patients 0.469036 radiation therapy patients 0.468456 dry mouth 0.687045 neck cancers 0.467921 radiation therapy 0.972855 Chronic dry mouth 0.472069 problems 0.532519	regular oral care 0.496586 oral care 0.520388 peroxide mouth rinses 0.475847 PDQ cancer information 0.50364 head 0.475462 mucous membranes 0.503677 mouth moist 0.469166 patient 0.472618 taste changes 0.470678 National Cancer Institute 0.465975 summary 0.488366 common oral complications 0.486948 Wipe mouth 0.467118 pain 0.536314 white blood cell 0.514465 tooth decay 0.48102 mouth guards 0.465834 gum disease 0.504216 salivary glands 0.547761 Managing Oral Complications 0.485092 PDQ summary 0.468583 mouth 0.82735 Different oral complications 0.468019 milder oral complications 0.467906	CLICK HERE
1628	National Cancer Institute	Html	en	Urethral Cancer Treatment (PDQ®)–Patient Version	Urethral cancer occurs in men and women and can spread quickly to lymph nodes near the urethra. Find out about risk factors, symptoms, tests to diagnose, prognosis, staging, and treatment for urethral cancer.	cancer treatment 0.362333 entire urethra 0.306444 lymph node dissection 0.557244 tissue 0.317299 body 0.398643 PDQ cancer information 0.410389 clinical trial search 0.378188 white blood cells 0.310278 bladder cancer 0.308764 clinical trials 0.773033 nearby lymph nodes 0.630197 cancer information summary 0.370147 clinical trial 0.499273 breast cancer prevention 0.294123 prostate gland 0.293841 patients 0.324988 invasive bladder cancer 0.301679 treatment clinical trial 0.300741 NCI PDQ cancer 0.319347 radiation therapy 0.651339 Urethral Cancer Treatment 0.356944 Treatment Editorial Board 0.30592 urethral cancer 0.837946 recurrent urethral cancer 0.334114	General information 0.298754 treatment 0.543719 new cancer treatments 0.306575 NCI-supported cancer 0.322826 cancer cells 0.450964 proximal urethral cancer 0.41852 urethral cancer spreads 0.344537 Cancer Information Service 0.306473 laser surgery 0.302658 patient 0.295185 treatment clinical trials 0.339398 anterior exenteration 0.294741 National Cancer Institute 0.373731 transurethral resection 0.314195 new treatment 0.34401 distal urethral cancer 0.388721 external radiation therapy 0.308401 cancer research process 0.298298 cancer clinical trials 0.402611 cancer information summaries 0.303961 comprehensive cancer information 0.304414 internal radiation therapy 0.302856 cancer 0.977674 standard treatment 0.307427	CLICK HERE
1674	National Cancer Institute	Html	en	Langerhans Cell Histiocytosis Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of childhood Langerhans Cell Histiocytosis.	Recurrent LCH 0.49021 cancer treatment 0.458844 childhood LCH lesions 0.545029 body 0.479436 high-risk multisystem LCH 0.563365 PDQ cancer information 0.430462 clinical trial search 0.417075 steroid therapy 0.417152 LCH lesions 0.646087 refractory childhood LCH 0.507141 Refractory LCH 0.491285 clinical trials 0.840496 LCH cells 0.723911 skin-only LCH 0.533026 cancer information summary 0.406099 clinical trial 0.546139 Langerhans cell histiocytosis 0.451003 patients 0.432765 LCH 0.976752 diagnose LCH 0.533565 lymph nodes 0.422079 treatment 0.665224 Progressive LCH 0.491974 BRAF gene 0.403636 LCH multisystem disease 0.521252	recurrent childhood LCH 0.508123 cancer cells 0.427036 pituitary gland 0.410888 childhood lch 0.600077 Adult LCH sections 0.511455 multisystem lch 0.599051 LCH trials 0.499932 LCH treatment 0.529717 treatment clinical trials 0.417639 National Cancer Institute 0.432317 effects cancer treatment 0.398781 small LCH lesions 0.540477 new treatment 0.409482 LCH bone lesions 0.547532 Adult LCH 0.522754 body systems 0.391142 LCH CNS 0.492291 bone marrow 0.4649 cancer clinical trials 0.44841 single-system lch 0.515862 progressive childhood LCH 0.507794 childhood LCH skin 0.522098 cancer 0.650545 information 0.432489	CLICK HERE
1805	National Cancer Institute	Html	es	Tratamiento del cáncer de ano (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de ano.	Anal Cancer Trial 0.489207 results from 0.31371 John M 0.347549 with external radiotherapy 0.314904 anal canal 0.794085 combined modality therapy 0.350825 Trial Working Party 0.324488 randomized intergroup study 0.336989 Radiation Therapy Oncology 0.354467 perianal epidermoid cancers 0.314329 Radiat Oncol Biol 0.493627 anal intraepithelial neoplasia 0.3483 Natl Cancer Inst 0.358284 Flam M 0.355801 epidermoid carcinoma 0.391708 patients with 0.3347 radiation therapy 0.487367 preoperative multidisciplinary therapy 0.316168 squamous carcinoma 0.31988 intraepitelial anal ii–iii 0.32888 Krall JM 0.319145 Cancer Trial Working 0.342892 estadio ii 0.314589 Pajak TF 0.321788 Therapy Oncology Group 0.342392	with anal squamous 0.330697 anal carcinoma 0.555894 patients with carcinoma 0.314283 adjuvant combined modality 0.322897 combined with chemotherapy 0.336207 Oncology Group study 0.357157 Cancer Research 0.342768 therapy combined with 0.337029 Definitive irradiation 0.321135 randomised ukcccr anal 0.326366 interim report 0.31903 versus radiotherapy 0.314135 Clin Oncol 0.342577 Sischy B 0.347382 Oncol Biol Phys 0.504444 UK Co-ordinating Committee 0.321139 anal cancer 0.987825 definitive nonsurgical treatment 0.344247 optimal radiation 0.320998 advanced anal canal 0.329424 UKCCCR Anal Cancer 0.435954 implantation combined with 0.313892 anal canal carcinoma 0.398943 Doggett RL 0.318887	CLICK HERE
2042	National Cancer Institute	Html	es	Exámenes de detección del cáncer de vejiga y otros cánceres uroteliales (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca de las pruebas que se usan para detectar sistemáticamente el cáncer de vejiga.	Cancer Inst Monogr 0.315885 Cancer Institute Surveillance 0.316979 urine cytology 0.306951 cuadro clínico 0.318123 Cancer Statistics Review 0.328453 transitional cell carcinoma 0.316775 Cancer registry problems 0.313029 Sin embargo 0.315264 American Cancer Society 0.340114 Hunt VB 0.306661 case-control study 0.305353 bladder cancer 0.978775 Young TB 0.311698 Bladder histological changes 0.316494 undergoing hematuria 0.308248 Malignant bladder tumors 0.31586 Can hematuria 0.308153 risk factors 0.306901 personas negras 0.307528 PDQ Exámenes 0.306867 patients with hematuria 0.310947 Messing EM 0.31983 Estados Unidos 0.311295 Natl Cancer Inst 0.403227 second cancers 0.320702	screening study using 0.305437 Bladder Cancer Group 0.328941 patients with 0.328907 neuropathic bladder 0.315447 SEER Cancer Statistics 0.328432 urinary tract 0.322774 Urol Clin North 0.310774 estadio t2+ 0.30573 detección casero 0.305242 Occup Med 0.308003 Cancer Facts 0.314556 bladder followed 0.315821 Noone AM 0.305423 National Cancer Institute 0.366947 Soloway MS 0.307825 Epidemiol Biomarkers Prev 0.327488 cell carcinoma 0.322375 asymptomatic microhematuria 0.311534 Clin North Am 0.316485 cell cytology screening 0.305294 bladder tumor 0.350128 invasive bladder 0.335021 bladder toxicity from 0.31599 transitional cell 0.318191	CLICK HERE
3529	National Cancer Institute	Html	es	Cáncer de próstata, nutrición y suplementos alimentarios (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos sobre el uso de la nutrición y los suplementos alimentarios para disminuir el riesgo de presentar cáncer de próstata o como tratamiento del mismo.	siglo xvii 0.306907 diario polyphenon 0.307426 productos alimenticios 0.340812 causa efectos 0.30879 té oolong 0.331426 calcio lácteo 0.324026 siguientes alimentos 0.308786 beneficios escasos 0.305604 productos lácteos 0.477796 fase ii 0.324128 vitamina d 0.307135 pacientes dosis 0.311906 futuros estudios 0.316382 hormonas masculinas 0.314232 hormonas sexuales masculinas 0.313427 llamada pcm 0.309543 posibles efectos 0.310927 insuficiencia hepática aguda 0.310772 ml /taza 0.306352 Estados Unidos 0.987475 menores concentraciones 0.310564 epigalocatequina gegc 0.310451 menor riesgo 0.310031 efectos secundarios dañinos 0.344646 siguientes observaciones 0.305279	efectos protectores 0.321928 histonas desacetilasas 0.307206 punica granatum l 0.307286 inyectó gegc 0.309986 cuerpo almacena calcio 0.328293 United States Preventive 0.312326 hiperplasia prostática benigna 0.310399 modelos animales 0.370702 vía oral 0.33411 cabo investigaciones 0.30894 lesiones tipo npi 0.310391 molestias estomacales 0.315997 ¿El calcio 0.323919 menor multiplicación 0.328691 suficientes pruebas 0.30615 partes distantes 0.305904 Services Task Force 0.311967 principales fuentes 0.306362 radicales libres 0.306952 corto plazo 0.30542 cabo estudios 0.372156 posibles beneficios 0.305916 Camellia sinensis 0.307372 ¿El té 0.326561	CLICK HERE
3674	National Cancer Institute	Html	en	About the Genomic Data Sharing (GDS) Policy	Find helpful information about the GDS Policy, including when the policy applies, example projects, and providing informed consent.	data 0.82822 subsequent research 0.542062 scale research projects 0.540547 case-by-case basis 0.523592 large-scale genomic data 0.566607 research 0.652936 research projects 0.576167 intramural research 0.556456 investigators 0.50707 future research 0.572423 genomic data 0.760118 Human Genome Research 0.527144 Sharing Repository list 0.531325 NIH repository 0.489091 research community 0.487992 non-human genomic data 0.67956 NIH-funded research projects 0.531999 broad sharing 0.547642 Intramural investigators 0.494528 Trans-NCI Data Sharing 0.55358 NIH Genomic Data 0.603222 NIH Deputy Director 0.524095 usual data 0.490789 data sharing 0.652134	NCI Scientific Program 0.534443 Rare Disease Act 0.50658 United States 0.504978 sample consent forms 0.527036 NCI-funded research 0.492053 small patient populations 0.504923 sample threshold 0.505219 alternative data sharing 0.62573 appropriate program directors 0.511229 appropriate NCI Program 0.550878 Phenotypic Data Subject 0.531651 intramural scientific director 0.629908 consent forms 0.555547 data sharing plan 0.62329 effective date 0.571535 smaller scale 0.517774 study data 0.489242 NCI Director 0.488407 NIH-designated data repositories 0.533934 data repositories 0.543247 Intramural projects 0.499743 gds policy 0.963933 time points 0.50548 Orphan Drug Act 0.506071	CLICK HERE
16831	National Cancer Institute	Html	en	Functional Genomics Research	NCI's Center for Cancer Genomics uses functional genomics to understand the impact of cancer genes and pathways, and how to target them effectively.	CTD² Network 0.438678 Wellcome Trust Sanger 0.539692 Cancer Target 0.513795 genome-wide techniques 0.446676 new ideas 0.464401 functional genomics 0.975263 genomic vulnerabilities 0.510701 functional genomics experiments 0.70252 clinical data 0.51781 abnormal proliferation 0.447258 functional cancer genomics 0.735243 functional genomic approaches 0.609867 new methods 0.442531 cutting-edge organoid 0.535662 Driver Discovery 0.445569 research community 0.441075 cancer care 0.532833 CTD2 Network 0.523145 structural genomics research 0.72197 large-scale genomic datasets 0.600198 cancer work 0.514288 cell models 0.464098 available drugs 0.442916 functional genomics research 0.95801 human tumors 0.440224	CRISPR-Cas9 technology 0.437797 particular genetic alterations 0.563867 gene perturbation experiments 0.559111 Cancer Research UK 0.609166 tumor organoid cultures 0.651279 cancer cells 0.526612 cancer cell lines 0.623629 publicly available bank 0.544919 Cancer Model Development 0.602943 genetic abnormalities 0.444289 new compounds 0.443968 Genome Characterization Pipeline 0.5568 structural genomics studies 0.680281 CCG researchers 0.496817 high-throughput drug screens 0.551758 clinical care 0.437267 publishing novel results 0.53823 patient biopsies 0.451112 petri dishes 0.439826 cancer genes 0.514196 cancer development 0.502413 next-generation cancer models 0.753989 Hubrecht Organoid Technology 0.640694 cancer biology 0.533186	CLICK HERE
16840	National Cancer Institute	Html	en	Companies Formed by PIs of the NCI Alliance for Nanotechnology in Cancer	The NCI Alliance for Nanotechnology in Cancer has continued to translate solutions from the bench to products. Find out the companies that have been formed by Alliance funded research.	clinical products 0.627038 Alliance members 0.614849 academic laboratories 0.654334 for-profit partners 0.714957 start-ups 0.300298 clinical communities 0.60175 venture capital funds 0.950483 investigators 0.301645 partnerships 0.289977 start-up companies 0.650807 patents 0.29414 large pharmaceutical companies 0.926075	translational research 0.68727 significant investment 0.618191 Alliance PIs 0.780886 efficient development 0.679103 IP 0.327964 Alliance model 0.651092 services 0.276826 start-up companies. 0.723832 technologies 0.28746 biotechnology firms 0.63767 form 0.28731 discoveries 0.300415	CLICK HERE